Ocular Therapeutix
OCUL
151 hedge funds and large institutions have $940M invested in Ocular Therapeutix in 2024 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 56 increasing their positions, 27 reducing their positions, and 34 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 27
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
5.17% more ownership
Funds ownership: 83.54% → 88.71% (+5.2%)
3% more funds holding
Funds holding: 147 → 151 (+4)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
17% less capital invested
Capital invested by funds: $1.13B → $940M (-$188M)
56% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $3.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.7M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$10.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$15.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.44M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$8.31M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$6.16M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$4.92M |
OCUL Hedge Fund Activity: Q2 2024 in Review
151 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2024, worth a combined $940M — down 17% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new OCUL positions and 34 closed out — a net gain of 5 holders — while 56 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $21.3M. The largest seller was Great Point Partners, exiting entirely with an estimated $15.7M sold.
- 151 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2024, up from 147 in Q1 2024.
- Funds reported $940M of Ocular Therapeutix stock for Q2 2024, down 17% quarter-over-quarter.
- 39 funds opened new Ocular Therapeutix positions in Q2 2024 and 34 closed out, a net change of +5 holders.
- The largest Ocular Therapeutix buyer in Q2 2024 was BlackRock, an estimated $21.3M added.
- The largest Ocular Therapeutix seller in Q2 2024 was Great Point Partners, an estimated $15.7M sold.
Based on aggregated 13F filings for Q2 2024.